Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for BeyondSpring Inc. (BYSI : NSDQ)
 
 • Company Description   
BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States.

Number of Employees: 40

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.21 Daily Weekly Monthly
20 Day Moving Average: 134,718 shares
Shares Outstanding: 40.32 (millions)
Market Capitalization: $89.10 (millions)
Beta: 0.17
52 Week High: $3.44
52 Week Low: $0.98
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -11.95% -14.59%
12 Week 82.64% 58.33%
Year To Date 35.58% 28.09%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
100 CAMPUS DRIVE WEST SIDE 4TH FLOOR SUITE 410
-
FLORHAM PARK,NJ 07932
USA
ph: 646-305-6387
fax: 646-882-4228
ir@beyondspringpharma.com http://www.beyondspringpharma.com
 
 • General Corporate Information   
Officers
Lan Huang - Chief Executive Officer and Director
Brendan Delaney - Director
Patrick Fabbio - Director
Matthew Kirkby - Director
Jiangwen Majeti - Director

Peer Information
BeyondSpring Inc. (CORR.)
BeyondSpring Inc. (RSPI)
BeyondSpring Inc. (CGXP)
BeyondSpring Inc. (BGEN)
BeyondSpring Inc. (GTBP)
BeyondSpring Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: G10830100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/11/25
Share - Related Items
Shares Outstanding: 40.32
Most Recent Split Date: (:1)
Beta: 0.17
Market Capitalization: $89.10 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - -
Current Ratio
06/30/25 - -
03/31/25 - 2.49
12/31/24 - 2.60
Quick Ratio
06/30/25 - -
03/31/25 - 2.49
12/31/24 - 2.60
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - -0.31
12/31/24 - -0.37
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©